Trevena announces OLINVYK data from ARTEMIS study

Trevena announced new topline OLINVYK data from the ARTEMIS study. The ARTEMIS study was an electronic medical records based assessment focused on clinical and health resource utilization outcomes at Cleveland Clinic and Wake Forest Baptist Health. The study reviewed OLINVYK-treated patients in the ~200 patient VOLITION study with comparable surgical patients treated with other IV opioids, at the same institutions and during the study period. New topline data includes data from OLINVYK-treated patients and matched patients at Cleveland Clinic, as well as measures of cost per admission at both Wake Forest Baptist Health and Cleveland Clinic for OLINVYK-treated and matched patients. Initial ARTEMIS data from Wake Forest Baptist Health was previously announced based on OLINVYK-treated patients compared to matched patients at that site. Overall Data from Cleveland Clinic and Wake Forest Baptist Health. OLINVYK-treated patients had a $8,756 reduction in average cost per admission and 1.4-day reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids. Based on the data we have to date, there was not a statistically significant difference in the average duration of time in the post-anesthesia care unit between OLINVYK-treated and matched patients. Cleveland Clinic Results. OLINVYK-treated patients had a $7,102 reduction in average cost per admission and a 0.9-day reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids at Cleveland Clinic. Wake Forest Baptist Health Results. OLINVYK-treated patients had a $10,339 reduction in average cost per admission compared to matched patients treated with other IV opioids at Wake Forest Baptist Health. The Company previously announced that OLINVYK-treated patients at this site had a 1.6 day reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids.